Report error Found 18 Enz. Inhib. hit(s) with Target = 'Vasopressin V2 receptor' and Ligand = 'BDBM50065115'
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 2.30nMAssay Description:Inhibition of [3H]AVP binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 23nMAssay Description:Inhibition of 1 nM AVP-induced cAMP accumulation in cells expressing human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 90nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:Displacement of P[3H]-AVP from isolated rat kidney medullary V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of [3H]-AVP binding to human V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Displacement of [3H]-AVP from human V2 receptor expressed in murine fibroblast cell line (LV2) membranesMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:In vitro binding affinity to human V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Displacement of [3H]AVP from human vasopressin V2 receptor expressed in mouse LV2 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Displacement of [3H]-AVP from human vasopressin V2-receptor expressed in murine fibroblast cell (LV2) membranesMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:In vitro inhibition of [3H]-AVP binding to human V2 receptor from murine fibroblast cell line (LV2)More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:Inhibition of [3H]-AVP binding to Dawley rat kidney medullary vasopressin V2 receptor.More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:Displacement of [3H]-AVP from vasopressin V2 receptor of rat kidney medulla.More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:Binding affinity to rat V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of [3H]-Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Displacement of [3H]-Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 91nMAssay Description:Inhibitory activity of the human V2 receptor was assessed by the accumulation of cAMP in transfected HEK-293 cells.More data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 91nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
